Gw Pharmaceuticals Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gw Pharmaceuticals Plc (GWPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gw Pharmaceuticals Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 559M vs 343M combined for tracked competitors (62.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+9.1% annualized vs trailing 12 months), vs decelerating (-89.5%) for its tracked peer group.
- Growth: Gw Pharmaceuticals Plc generated 26.4% revenue growth year over year in Q1 2021, vs -76.6% for its tracked competitors combined.
- Profitability: Its -12.9% net margin compares with -961.7% for the peer group.
- Peer revenue share: Gw Pharmaceuticals Plc accounted for 94.4% of combined revenue among its tracked peer group, up from 75.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.63M compares with $0.61M for the peer group (1.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GWPH Sales vs. its Competitors, Q1 2021
Gw Pharmaceuticals Plc reported revenue growth of 26.39 % year on year in Q1 2021, above its competitors' combined revenue change of -76.58 %.
With a net margin of -12.91 %, Gw Pharmaceuticals Plc achieved higher profitability than its competitors (-961.70 %).
Gw Pharmaceuticals Plc generated 94.42 % of the combined sales of its peer group, up from 75.82 % a year earlier.
Gw Pharmaceuticals Plc vs. its Competitors, Q1 2021
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Gw Pharmaceuticals Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Gw Pharmaceuticals Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Gw Pharmaceuticals Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 26.4% for Gw Pharmaceuticals Plc. Gw Pharmaceuticals Plc's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Gw Pharmaceuticals Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gw Pharmaceuticals Plc | No | Yes | Yes | No |
| Competitors combined (18) | ||||
| High-Confidence Competitors (8) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GWPH Stock Performance relative to its Competitors
GWPH Stock Performance relative to High-Confidence Competitors
GWPH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 2 | Evoke Pharma Inc | 282.9% | Outperformed |
| 3 | Promis Neurosciences inc | 282.9% | Outperformed |
| 4 | Nu med Plus Inc | 282.9% | Outperformed |
| 5 | Cv Sciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Gw Pharmaceuticals Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Gw Pharmaceuticals Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Gw Pharmaceuticals Plc | 6,907.57 | 559.04 |
| Avadel Pharmaceuticals Plc | 2,189.59 | 248.76 |
| Promis Neurosciences inc | 99.65 | - |
| Zynerba Pharmaceuticals Inc | 65.20 | - |
| Marinus Pharmaceuticals Inc | 31.48 | 31.47 |
| Intelgenx Technologies Corp | 28.64 | 1.04 |
| SUBTOTAL | 9,436.57 | 902.08 |
Sign in to see all competitors of Gw Pharmaceuticals Plc.
Sources: Gw Pharmaceuticals Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Gw Pharmaceuticals Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Gw Pharmaceuticals Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ovid Therapeutics Inc | Named by the company | 85% |
| Cv Sciences Inc | Named by the company | 85% |
| Stoke Therapeutics Inc | Named by the company | 85% |
| Can B Corp | Named by the company | 85% |
| Pharmacyte Biotech Inc | Named by the company | 85% |
| Enveric Biosciences Inc | Named by the company | 85% |
| Kuvatris Therapeutics Inc | Named by the company | 85% |
| Cnbx Pharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Gw Pharmaceuticals Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Gw Pharmaceuticals Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Avadel Pharmaceuticals Plc | Reportable 100.00 % |
| Evoke Pharma Inc | Pharmaceutical Products 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Gw Pharmaceuticals Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Gw Pharmaceuticals Plc | 6,908 | 629,547 | -23,346 |
| Avadel Pharmaceuticals Plc | 2,190 | 1,615,338 | -1,805 |
| Promis Neurosciences inc | 100 | - | -3,838,931 |
| Zynerba Pharmaceuticals Inc | 65 | - | -3,131,841 |
| Marinus Pharmaceuticals Inc | 31 | 190,703 | -851,461 |
| Intelgenx Technologies Corp | 29 | 34,733 | -367,667 |
| PEERS TOTAL | 2,529 | 610,392 | -675,498 |
Sign in to see all peers for Gw Pharmaceuticals Plc.
Gw Pharmaceuticals Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Intelgenx Technologies Corp | Europe 64.37 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Gw Pharmaceuticals Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 56.33 % | 64.89 % (avg) | -8.6 pp |
| Operating Margin | -11.73 % | industry median | +98.0 pp |
| EBITDA Margin | -2.41 % | -7.21 % (avg) | +4.8 pp |
| Capital Intensity (Capex / Revenue) | 2.91 % | 4.92 % (avg) | -2.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Gw Pharmaceuticals Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 9.2x | 4.5x | +4.7x |
| Return on Equity | -2.83 % | industry aggregate | -10.95 % |
| Return on Invested Capital | -4.37 % | -2.95 % (avg) | -1.42 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Gw Pharmaceuticals Plc's Strategic Group Map
Every company in Gw Pharmaceuticals Plc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Gw Pharmaceuticals Plc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Gw Pharmaceuticals Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.91 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Gw Pharmaceuticals Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Gw Pharmaceuticals Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Gw Pharmaceuticals Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Gw Pharmaceuticals Plc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Gw Pharmaceuticals Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 98.0 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+9.1% annualized vs trailing 12 months).
Weaknesses
- Return on equity 11.0 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (44.40 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-89.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Gw Pharmaceuticals Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Gw Pharmaceuticals Plc | 3.29 | 4.93 | - |
| Avadel Pharmaceuticals Plc | 1.14 | 2.76 | - |
| Promis Neurosciences inc | 3.80 | 4.19 | - |
| Zynerba Pharmaceuticals Inc | 4.71 | 5.10 | - |
| Marinus Pharmaceuticals Inc | 2.93 | 2.83 | - |
| Intelgenx Technologies Corp | 0.15 | 0.28 | - |
Sign in to see all peers for Gw Pharmaceuticals Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Gw Pharmaceuticals Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Gw Pharmaceuticals Plc | Q1 2021 | +26.4 % | - |
| Avadel Pharmaceuticals Plc | Q3 2025 | +55.3 % | - |
| Promis Neurosciences inc | Q2 2026 | - | - |
| Zynerba Pharmaceuticals Inc | Q2 2023 | - | - |
| Marinus Pharmaceuticals Inc | Q3 2024 | +16.4 % | - |
| Intelgenx Technologies Corp | Q1 2024 | +7.4 % | - |
| PEERS TOTAL | +33.2 % | - |
Sign in to see all peers for Gw Pharmaceuticals Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Gw Pharmaceuticals Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Gw Pharmaceuticals Plc | Q1 2021 | +9.6 % | +23.9 % |
| Avadel Pharmaceuticals Plc | Q3 2025 | -33.1 % | - |
| Promis Neurosciences inc | Q2 2026 | - | - |
| Zynerba Pharmaceuticals Inc | Q2 2023 | - | - |
| Marinus Pharmaceuticals Inc | Q3 2024 | +56.9 % | +1,210.6 % |
| Intelgenx Technologies Corp | Q1 2024 | - | - |
Sign in to see all peers for Gw Pharmaceuticals Plc.
Gw Pharmaceuticals Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Gw Pharmaceuticals Plc | - | - | - |
| Avadel Pharmaceuticals Plc | - | - | - |
| Promis Neurosciences inc | - | - | - |
| Zynerba Pharmaceuticals Inc | - | - | - |
| Marinus Pharmaceuticals Inc | - | - | - |
| Intelgenx Technologies Corp | - | - | - |
Sign in to see all peers for Gw Pharmaceuticals Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Gw Pharmaceuticals Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Gw Pharmaceuticals Plc | - | 12.36 |
| Avadel Pharmaceuticals Plc | - | 8.80 |
| Promis Neurosciences inc | - | - |
| Zynerba Pharmaceuticals Inc | - | - |
| Marinus Pharmaceuticals Inc | - | 1.00 |
| Intelgenx Technologies Corp | - | 27.49 |
| PEERS AVERAGE | - | 10.46 |
Sign in to see all peers for Gw Pharmaceuticals Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.